ArticleBMC microbiology2025
Comparison of ciprofloxacin and aminoglycoside susceptibility testing for ceftriaxone non-susceptible Enterobacterales by disk diffusion and VITEK 2 vs. broth microdilution using updated Clinical and Laboratory Standards Institute breakpoints.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Patients and Surfaces: Integrated Clinical-Environmental Surveillance of MDR Gram-Negative Bacteria in Critical-Care Units (Karachi, 2024-2025).Microorganisms · 2025Article
- A Comparative Study of Extended Gentamicin and Tobramycin Release and Antibacterial Efficacy from Palacos and Simplex Acrylic Cements.Microorganisms · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFluoroquinolones and aminoglycosides are potential treatment choices in the setting of increasingly multi-drug resistant Enterobacterales. The Clinical & Laboratory Standards Institute (CLSI) breakpoints for fluoroquinolones and aminoglycosides in the Enterobacterales were revised in 2019 and 2022, respectively. However, performance of existing widely used automated systems, such as the VITEK 2 AST-N391 card, has not been extensively tested for MDR isolates at these new breakpoints.
objectiveTo assess performance of the new breakpoints for ciprofloxacin, gentamicin, and tobramycin on the VITEK 2 system (bioMérieux, France) and disk diffusion by comparing to broth microdilution for ceftriaxone nonsusceptible Enterobacterales.
methodsNinety-four ceftriaxone non-susceptible Escherichia coli and Klebsiella pneumoniae isolates were identified between January 2021-June 2023. Broth microdilution was used as the reference standard against which disk diffusion and VITEK 2 susceptibility testing were compared. For the Vitek 2, we used the AST-N391 card and interpreted the results according to the updated CLSI breakpoints.
resultsOverall, 22.3% of isolates were susceptible to ciprofloxacin by BMD. Compared to BMD, disk diffusion had an overall minor error rate of 7.4% (95%CI 3.0-14.7%) with 0 major or very major errors (97.5% CI 0-3.8%). For the VITEK 2, a minor error rate of 13.8% (95% CI 7.6-22.5%), major error rate 19.0% (95%CI 7.7-40.0%) and very major error rate 0% (97.5%CI 0-3.8%) was noted. By comparison, 69.1% and 56.4% of isolates were susceptible to gentamicin and tobramycin, respectively. Disk diffusion and the VITEK 2 system both correctly categorized 100% of gentamicin susceptible and non-susceptible isolates. For tobramycin, disk diffusion had a 3.2% rate of misclassification (all minor errors) and the VITEK 2 had 2.1% rate of misclassification (all minor errors). There were no major or very major errors.
conclusionsOur findings suggest that both disk diffusion and to a greater extent the AST-N391 card for the VITEK 2 system will overcall non-susceptibility according to current CLSI breakpoints for ciprofloxacin. By contrast, the existing AST-N391 VITEK 2 card can likely be used to correctly infer susceptibility to gentamicin and tobramycin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.